language_icon
EN
HI

Biocon Share price

BIOCON

356.7

1.10 (-0.31%)
NSE
BSE
Last updated on 23 Apr, 2026 | 15:29 IST
Today's High

364.80

Today's Low

355.60

52 Week Low

308.45

52 Week High

424.95

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Biocon Chart

Biocon Share Key Metrics

Volume
22.88 L
Market Cap
57996.08 CR
LTQ@LTP
152@356.70
ATP
360.11
Var Margin
15.47 %
Circuit Range
322.05-393.55
Delivery %
58.59 %
Value
82.38 CR
ASM/GSM
No
Market Lot
1

Summary

Biocon share price stands at ₹356.7 at 23 Apr, 2026 | 15:29. The stock Biocon intraday movement has stayed between ₹355.60 and ₹364.80, while on a 52-week basis it has fluctuated from ₹308.45 to ₹424.95.
In terms of trading activity, Biocon has recorded a volume of 2287523 shares. The Biocon has a market cap of ₹1620907773. The stock’s Average Traded Price (ATP) stands at ₹36011, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 152, 35670.
The Biocon operates within a circuit range of ₹322.05-393.55 – ₹322.05-393.55, with a Value of ₹82.38 CR. The Delivery Percentage for the day is 58.59%. Additionally, Biocon currently falls under the No framework, and trades with a market lot size of 1.

Biocon Fundamentals

View More
P/E Ratio

96.95

P/B Ratio

1.55

Div. Yield

0.14

Sector P/E

63.84

Sector P/B

3.48

Sec. Div. Yield

0.57

Biocon Resistance and Support

Pivot 358.83

Resistance

First Resistance

361.46

Second Resistance

365.13

Third Resistance

367.76

Support

First Support

355.16

Second Support

352.53

Third Support

348.86

Biocon Futures & Options

356.7

-1.1 (-0.31%)

link_white_icon

Biocon Option Chain

View Price, OI, Greeks & More...
View All

28APR26

357.75

-0.40 (0.11%)

26MAY26

360.25

0.00 (0.00%)

30JUN26

362.60

0.50 (0.14%)

BIOCON|28APR26 CE 355.00

5.50

-0.9 (-14.06%)

BIOCON|28APR26 PE 360.00

5.35

-0.45 (-7.76%)

Biocon Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

54.45%

Mutual Fund

13.75%

Insurance

6.9%

Foreign Institutional Investors

7.39%

Domestic Institutional Investors

1.06%

Retail

16.45%

Others

0%

Total Promoters
MAR '25
60.64%
JUN '25
54.45%
SEP '25
54.45%
DEC '25
54.45%

Biocon Corporate Actions

DateAgenda
2026-02-12Quarterly Results
2025-11-11Quarterly Results
2025-10-01Redemption (Part) of NCD
2025-08-07Quarterly Results
2025-05-08Audited Results & Final Dividend
2025-04-23Others
2025-04-04To consider Fund Raising
2025-01-30Quarterly Results & Others
2025-01-27Others

Biocon News

Biocon gains after Health Canada nod for cancer, osteoporosis drugs

Biocon's subsidiary, Biocon Biologics, received Health Canada approval for its biosimilars Yesintek and Yesintek I.V., which are biosimilars of ustekinumab. This approval, granted on October 17, 2025, allows for their commercial launch in Canada by mid-October 2025, strengthening the company's presence in the North American immunology market, valued at over CAD 1 billion annually.
Apr 21 2026 10:04:00

Biocon Limited

Biocon received Health Canada approval on April 3, 2026, for its biosimilars Bosaya (denosumab) and Vevzuo (denosumab). This expands access to high-quality biologic therapies for osteoporosis and cancer-related bone conditions in key global markets.
Apr 21 2026 08:04:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Biocon receives Health Canada approval for its denosumab biosimilars, Bosaya™ and Vevzuo™, on April 3, 2026. These biosimilars are indicated for osteoporosis and various cancer-related bone conditions.
Apr 21 2026 08:04:00

Biocon Limited

Biocon Limited has issued a reminder to shareholders holding physical shares to update their KYC details. This is crucial for shareholders to continue receiving payments such as dividends and interest, aligning with SEBI Master Circular dated February 06, 2026.
Apr 20 2026 20:04:00

Biocon Limited

Biocon Pharma Ltd received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg). This approval strengthens the company's diabetes portfolio, with manufacturing to occur at its FDA-approved facilities.
Apr 08 2026 08:04:00

Biocon Limited

Biocon management will participate in the HSBC Global Investment Summit 2026 and an Investor Roadshow from April 14-17, 2026. These meetings will take place in Hong Kong and Singapore to engage with analysts and investors.
Apr 07 2026 20:04:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Biocon management will participate in the HSBC Global Investment Summit in Hong Kong and an Investor Roadshow in Singapore from April 14-17, 2026. These meetings are with analysts and institutional investors; no unpublished price sensitive information will be disclosed.
Apr 07 2026 20:04:00

Biocon Limited

Biocon announced the U.S. commercial launch of its denosumab biosimilars, Bosaya and Aukelso, for osteoporosis and cancer-related bone conditions. These products received interchangeable designation from the U.S. FDA in September 2025, enabling broader access to high-quality treatment options for patients.
Apr 07 2026 16:04:00

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Biocon announced the U.S. commercial launch of its denosumab biosimilars, Bosaya™ and Aukelso™. These products are now available nationwide after receiving interchangeable designation from the U.S. FDA in September 2025.
Apr 07 2026 16:04:00

Biocon Ltd - 532523 - Amendment To Trust Deed

Biocon Limited amended its Employees Welfare Trust Deed, changing the composition of its Trustees. Two existing Trustees resigned, and two new Trustees were appointed, effective April 1, 2026, to manage the Employee Welfare Trust.
Mar 27 2026 12:03:00
Read More

About Biocon

NSE : 11373  
BSE : 532523  
ISIN : INE376G01013  

HISTORY AND CERTAIN CORPORATE MATTERSOur Company was incorporated as Biocon India Private Limited onNovember 29 1978 under the Companies Act. The word `Private' wasdeleted from our name under the provisions of Section 43A(2) of theCompanies Act with effect from July 1 1995. Thereafter our Company wasconverted to a private limited company under the provisions of Section43(2A) of the Companies Act with effect from December 21 2000. It wasreconverted into a public limited company on June 18 2001. The name ofour Company was changed from Biocon India Limited to Biocon Limited anda fresh certificate of incorporation consequent on change of name wasissued by the RoC on November 19 2003.Our Corporate StructureOur existing corporate structure is as under:Biocon LimitedClinigene International PrivateLimited (100.00%)Biocon Biopharmaceuticals PrivateLimited (51.00%)Syngene International PrivateLimited (99.99%)Interest of Promoters Directors and Key Managerial PersonnelExcept as stated in ?Related Party Transactions? on page 84 of this RedHerring Prospectus and to the extent of shareholding in our Companythe Promoters do not have any other interest in our business.Our Promoters have significant rights in our Company under the terms ofour Articles of Association. For additional information please referto the section entitled ?Main Provisions of Articles of Association ofBiocon Limited? on page 168 of this Red Herring Prospectus.Except to the extent of their compensation and to the extent of ESOPif any as mentioned on page 165 of this Red Herring Prospectus andtheir shareholding or shareholding of companies they represent theDirectors other than Promoter Directors do not have any otherinterest in our Company. Our Director Mr. John Shaw is the husband ofour Chairman & Managing Director Ms. Kiran Mazumdar-Shaw. OurDirector Prof. Ravi Mazumdar is the brother of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw. Our alternate Director Prof.Catherine Rosenberg is the sister-in-law of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw.The key managerial personnel of our Company do not have any interest inour Company other than to the extent of the remuneration or benefits towhich they are entitled to as per their terms of appointment andreimbursement of expenses incurred by them during the ordinary courseof business and to the extent of the Equity Shares held by them in theCompany if any and options granted to them under the ESOP.

Read More

Biocon Management

NamePosition
Kiran Mazumdar-ShawChairperson
Ravi Rasendra MazumdarNon Independent & Non Executive Director
View More

Biocon FAQs

The Buying Price of Biocon share is 356.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Biocon stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Biocon shares is 96.95. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Biocon shares is 1.55. Useful to assess the stock's value relative to its book value.

To assess Biocon’s valuation compare Sector P/E, P/B which are 63.84 & 3.48 with sector averages, along with growth rates and financial metrics.

The Market Cap of Biocon is 57996.08 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Biocon share price is 424.95 & 308.45. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Biocon belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost